¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦55ȸ Ãß°è±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2021-11-06

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦55ȸ Ãß°è±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2021-11-06
±³À°ÀÏÀÚ : 2021-11-06
±³À°Àå¼Ò : ¼­¿ï ÄÜ·¡µå È£ÅÚ  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà) Á¦55ȸ Ãß°è±¹Á¦Çмú´ëȸ (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑ°íÇ÷¾ÐÇÐȸ
´ã´çÀÚ : ±èÈñÁÖ
¿¬¶ôó : 02-565-3350  
À̸ÞÀÏ : ksh@koreanhypertension.org      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, ½Å°æ°ú, °¡Á¤ÀÇÇаú»ý¸®ÇÐ, ¾à¸®ÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°,      
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 29 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í *µî·Ïºñ : »çÀüµî·Ï-±³¼ö ¹× Àü¹®ÀÇ Á¤È¸¿ø(6¸¸¿ø), Á¤È¸¿ø ¿Ü(8¸¸¿ø) / Àü°øÀÇ ¹× ±âŸ(4¸¸¿ø) / °£È£»ç,¿µ¾ç»ç, ¾à»ç(2¸¸¿ø) / 65¼¼ ÀÌ»ó Á¤È¸¿ø&Çлý(¹«·á) *ÇöÀåµî·ÏÀº ¾øÀ½      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-06 Rooom A 08:00~08:50 Industrial Breakfast Symposium I  ÀÌÀç¿ì(ÃáÇغ´¿ø) 
±³À°½Ã°£ 11-06 Rooom B 08:00~08:50 Industrial Breakfast Symposium II  À̹æÇå(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 08:00~08:20 The importance of TG((TriGlyceride) management and a review of clinical trial of Fenofibrate choline  ¹Ú¸í¼ö(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 08:20~08:40 The Benefit of SPC(Single Pill Combinations) for Hypertensive patients with Dyslipidemia  ¼ÕÀϼ®(°æÈñÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom D 08:00~08:50 Industrial Breakfast Symposium IV  À¯¼®Èñ(LSK Global PS) 
±³À°½Ã°£ 11-06 Rooom A 09:00~09:15 Blood pressure lowering effect of SGLT2(Sodium Glucose Co-Transporter 2) inhibitor and HF(Heart Failure)  ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 09:15~09:30 Ambulatory blood pressure monitoring in HFrEF(Heart Failure with Reduced Ejection Fraction): Can it be a predictor of worsening?  Takahiro Komori(Japan) 
±³À°½Ã°£ 11-06 Rooom A 09:30~09:45 Hypertension treatment in HFpEF(Heart Failure with Preserved Ejection Fraction)  ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 09:45~10:00 Visit-to-visit blood pressure variability and HF(Heart Failure)  ÀÌÁÖÈñ(ÃæºÏÀÇ´ë) 
Åä·Ð 11-06 Rooom A 10:00~10:15 ÆгΠÅäÀÇ  À̼±±â, ½ÅÁ¤ÈÆ, ±èºÀÁØ(ÇѸ²ÀÇ´ë, ÇѾçÀÇ´ë, °í½ÅÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 09:00~09:15 Blood pressure variability and atrial fibrillation  À̼ҷÉ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 09:15~09:30 Blood pressure variability and white coat and masked hypertension  ±è¼ÛÀÌ(Á¦ÁÖÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 09:30~09:45 Blood pressure variability and nighttime and early morning blood pressure pattern  ¹Ú»ó¹Î(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 09:45~10:00 Blood pressure variability and its therapeutic implication  ±èÇý¹Ì(Áß¾ÓÀÇ´ë) 
Åä·Ð 11-06 Rooom B 10:00~10:15 ÆгΠÅäÀÇ  ¹Ú»óÇö, ±è¹Ì³ª, ±èÀ̽Ä, ÀÌÀº¹Ì(À»ÁöÀÇ´ë, °í·ÁÀÇ´ë, ÀüºÏÀÇ´ë, ¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 09:00~09:15 Associations between pregnancy hypertensive disorders and common cardiovascular disorders: The CALIBER(Cardiovascular Research using Linked Bespoke Studies and Electronic Health Records) study  ¼³»óÈÆ(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 09:15~09:30 An update on the pathophysiology of preeclampsia  Á¶ÀÎÁ¤(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 09:30~09:45 Threshold and target blood pressure for drug therapy in gestational hypertension  ¹ÚÀçÇü(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 09:45~10:00 How to guide and manange postnatal hypertensive women  ±èÁ¤¼ö(ºÎ»êÀÇ´ë) 
Åä·Ð 11-06 Rooom C 10:00~10:15 ÆгΠÅäÀÇ  ÀÌ»óÇö, ÀÓ°æÈñ, ±èÇüÀ±(ºÎ»êÀÇ´ë, µ¿¾ÆÀÇ´ë, Àü³²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom D 09:00~09:15 How to use home blood pressure monitors in clinical practice  ±èÀÎö(°è¸íÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom D 09:15~09:30 Nocturnal hypertension and role of home blood pressure monitoring  ·ùµ¿¿­(°­¿øÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom D 09:30~09:45 Methodological issues in home blood pressure monitoring  ½ÅÁøÈ£(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom D 09:45~10:00 Wearable devices and telemonitoring  ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 11-06 Rooom D 10:00~10:15 ÆгΠÅäÀÇ  ÀÌÁÖÈñ, Á¶µ¿Çõ, Á¶À翵(ÃæºÏÀÇ´ë, ¿¬¼¼¿øÁÖÀÇ´ë, Àü³²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 10:25~11:00 Recent Progress and Future Perspective of Hypertension Research  Youngsuk Oh(USA) 
±³À°½Ã°£ 11-06 Rooom A 11:10~11:40 Industrial Symposium I  Æí¿í¹ü(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 11:10~11:25 Journey of Valsartan to Provide CV(Cardiovascula) Protection for Patients at risk  ¹ÚÁغó(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 11:25~11:40 Earliest start of essential treatment & Latest finish in patient journey of HFrEF(Heart Failure with Reduced Ejection Fraction)  ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 11:10~11:40 Maximizing benefits in hypertension management with Perindopril and Indapamide  ±èÀÎö(°è¸íÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom D 11:10~11:25 New LDL-C(Low-Density Lipoprotein Cholesterol) Guidelines on Very High-risk Group : The Lower, The Better!  ±èÇöÁø(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom D 11:25~11:40 ¡®Higher Risk, Higher Benefit¡¯ Strategy with Evolocumab in Post-MI(Myocardial Infarction)  ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 11:50~12:25 Young Investigator Award  ±è±ÙÈ£, ÀÓ»óÇö(ÇѾçÀÇ´ë, °¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 11:50~12:25 Industrial Symposium V  ¼ÕÀϼ®(°æÈñÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 11:50~12:25 Industrial Symposium VII  ±è¹®Àç(¼øõÀÇ·áÀç´Ü) 
±³À°½Ã°£ 11-06 Rooom A 12:35~13:20 Luncheon Symposium IV  ±èÁ¾Áø(Â÷ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 12:35~13:00 The role of s-amlodipine in elderly hypertensive patients  ¹Ú»ó¹Î(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 12:35~12:55 The Recent Trend of Simultaneous Management of Hypertension and Dyslipidemia  ÁÖÇüÁØ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 12:55~13:15 Combination therapy of antihypertensive drugs for CV(Cardiovascula) protection  Á¤Çý¹®(°æÈñÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 13:30~13:45 Assessment of psychologic problem in elderly hypertensive patients  ½Åö¹Î(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 13:45~14:00 Resistant hypertension in elderly  ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 14:00~14:15 Role of ABPM(Ambulatory Blood Pressure Monitoring) in elderly hypertensive patients  Miguel Camafort-Babkowski(Spain) 
±³À°½Ã°£ 11-06 Rooom A 14:15~14:30 Achieving target blood pressure in older adults: Beyond the guidelines  ±è±¤ÀÏ(¼­¿ïÀÇ´ë) 
Åä·Ð 11-06 Rooom A 14:30~14:45 ÆгΠÅäÀÇ  ÀÌÇØ¿µ, Ȳ°æ±¹, ±èÇзÉ(¼­¿ïÀÇ´ë, ÃæºÏÀÇ´ë, ¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 13:30~13:45 Mechanisms of the effects of Gut Microbiome  ¿ÀÁø°æ(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 13:45~14:00 Gut Microbiota in Hypertension  Á¶Á¤¼±(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 14:00~14:15 Gut Microbiome in Korean Patients  ±èÇüÀ±(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 14:15~14:30 Fecal Microbiota Transplantation  ±ÇűÙ(°¡Å縯ÀÇ´ë) 
Åä·Ð 11-06 Rooom B 14:30~14:45 ÆгΠÅäÀÇ  ¹ÚÂù¼®, Á¶À翵, Çã¶õ(°¡Å縯ÀÇ´ë, Àü³²ÀÇ´ë, ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 13:30~13:45 Introduction of Sedentary behavior and health  ÀÓÁ¤ÁØ(¼­¿ï´ëÇб³) 
±³À°½Ã°£ 11-06 Rooom C 13:45~14:00 Sedentary behavior and metabolic disease  ¹Ú¼öÇö(Çѱ¹½ºÆ÷Ã÷Á¤Ã¥°³¹ß¿ø) 
±³À°½Ã°£ 11-06 Rooom C 14:00~14:15 Sedentary behavior and CVD(Cardiovascular Disease)  ±è¿ëȯ(°­¸ª¿øÁÖ´ëÇб³) 
±³À°½Ã°£ 11-06 Rooom C 14:15~14:30 Çѱ¹ÀÎÀÇ Sedentary behavior ÇöȲ°ú °³¼± Àü·«  ¹ÚÇöÅÂ(µ¿¾Æ´ëÇб³) 
Åä·Ð 11-06 Rooom C 14:30~14:45 ÆгΠÅäÀÇ  ÀÌ¿Â, À̽¿±, °­ÇöÁÖ(Çѱ¹½ºÆ÷Ã÷Á¤Ã¥°úÇпø, °¡Å縯°üµ¿´ëÇб³, ¼øõÇâ´ëÇб³) 
±³À°½Ã°£ 11-06 Rooom D 13:30~13:45 Overview of Biomarker in Hypertension  ÃÖ¼®¿ø(Áß¾Óº¸Èƺ´¿ø) 
±³À°½Ã°£ 11-06 Rooom D 13:45~14:00 Biomarker of Vascular Damage  Á¶µ¿Çõ(¿¬¼¼¿øÁÖÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom D 14:00~14:15 Biomarker of Renal Damage  ±è¿ìÇö(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom D 14:15~14:30 Biomarker of Cardiac Damage  Á¤¹ÌÇâ(ÇѸ²ÀÇ´ë) 
Åä·Ð 11-06 Rooom D 14:30~14:45 ÆгΠÅäÀÇ  ±èÀÀÁÖ, ½Å¹Ì½Â, ÃÖ¼ºÈÆ, ÇѼº¿ì(°í·ÁÀÇ´ë, °¡ÃµÀÇ´ë, ÇѸ²ÀÇ´ë, ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 14:55~15:10 Controversy on the reproducibility of ABPM(Ambulatory Blood Pressure Monitoring) parameters  Á¤ÀÎÇö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 15:10~15:25 Comparison among Auscultatory, Tonometry and Oscillometric Methods for ABPM(Ambulatory Blood Pressure Monitoring)  ¹Ú»ó¹Î(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 15:25~15:40 Three Methods to Evaluate Nocturnal Blood Pressure  Takayoshi Ohkubo(Japan) 
±³À°½Ã°£ 11-06 Rooom A 15:40~15:55 Drug Therapy to Reduce Ambulatory Central Blood Pressure  È²¿ø¹Î(°Ç¾çÀÇ´ë) 
Åä·Ð 11-06 Rooom A 15:55~16:10 ÆгΠÅäÀÇ  °­½ÃÇõ, ±èÇзÉ, Á¶Á¤¼±(¼­¿ïÀÇ´ë, ¼­¿ïÀÇ´ë, °¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 14:55~15:10 Epidemiology of resistant hypertension: global perspective & Korean  ¹ÚÁøÁÖ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 15:10~15:25 Updates in sleep apnea in patients with hypertension  ÃÖÀÚ¿¬(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 15:25~15:40 Differential diagnosis of endocrine hypertension  ±èÁ¤Èñ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 15:40~15:55 The current status of devices for the treatment of resistant hypertension  Á¶Áø¸¸(°æÈñÀÇ´ë) 
Åä·Ð 11-06 Rooom B 15:55~16:10 ÆгΠÅäÀÇ  ¹®À翬, ÃÖÀçÇõ, ÃÖö¿õ(Â÷ÀÇ´ë, ÇѸ²ÀÇ´ë, °í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 14:55~15:10 Insufficient sleep and blood pressure  ±è´ë¿µ(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 15:10~15:25 Insomnia and blood pressure  ¼ÛÆĸá¶ó(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 15:25~15:40 Sleep-Disordered Breathing and blood pressure  º¯Á¤ÀÍ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom C 15:40~15:55 Impact of hypoxia during sleep on neurological outcome among stroke patients  ±èÄ¡°æ(°í·ÁÀÇ´ë) 
Åä·Ð 11-06 Rooom C 15:55~16:10 ÆгΠÅäÀÇ  ÇѼöÇö, ¹Ú¹«¼®, ±è¿¹¸²(Áß¾ÓÀÇ´ë, ÀÌÈ­ÀÇ´ë, ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom D 15:35~15:55 °í·É °íÇ÷¾ÐÀÇ Áø´Ü°ú ÃʱâÄ¡·á  ÃÖ¼ºÈÆ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom D 15:55~16:15 ÀþÀº °íÇ÷¾ÐÀÇ Áø´Ü°ú ÃʱâÄ¡·á  ³ªÁø¿À(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom D 16:15~16:35 °íÇ÷¾Ð ¾àÁ¦ÀÇ ´Ü°èÀû Áõ·®¹æ¹ý  ±èÁÖÇÑ(Àü³²ÀÇ´ë) 
Åä·Ð 11-06 Rooom D 16:35~16:50 ÆгΠÅäÀÇ  ½ÅÁøÈ£, ÀÌÇØ¿µ, Á¤¿íÁø(ÇѾçÀÇ´ë, ¼­¿ïÀÇ´ë, °¡ÃµÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 16:20~16:50 Brain renin angiotensin system in the management of hypertension and heart failure  Catherine Llorens-Cortes(France) 
±³À°½Ã°£ 11-06 Rooom A 17:00~17:15 Mechanisms of Relation of Dietary salt to Blood Pressure  ÃÖÈ«»ó(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 17:15~17:30 Who are Salt sensitive? (diagnosis and risk factor)  À̹«¿ë(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom A 17:30~17:45 Methodologically robust or flawed studies in salt and hypertension  Á¤¹ÌÇâ(ÇѸ²ÀÇ´ë) 
Åä·Ð 11-06 Rooom A 17:45~18:00 Tissue sodium excess: nature and implications for hypertension  Giacomo Rossitto(Italy) 
Åä·Ð 11-06 Rooom A 18:00~18:15 ÆгΠÅäÀÇ  À̱Լ·, ¿ÀÁø°æ, ÁøÁ¤¿¬(°¡Å縯ÀÇ´ë, Ãæ³²ÀÇ´ë, À»ÁöÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 17:00~17:15 Air pollution, hypertension and cardiovascular disease  ¹Ú»ó¹Î(¼­¿ï´ëÇб³) 
±³À°½Ã°£ 11-06 Rooom B 17:15~17:30 Noise pollution and hypertension  À¯ÁøÇÏ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 17:30~17:45 Occupational stressors and hypertension  °­¸ð¿­(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 17:45~18:00 Temperature and hypertension -  Àü°æÇö(Àϻ꺴¿ø) 
Åä·Ð 11-06 Rooom B 18:00~18:15 ÆгΠÅäÀÇ  ±èÈ¿Àº, ¼­Áö¿ø, Á¤Çý¹®, Çã¶õ(¿¬¼¼ÀÇ´ë, ¿¬¼¼ÀÇ´ë, °æÈñÀÇ´ë, ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 17:00~17:20 Pros  Á¶»óÈ£(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 17:20~17:40 Cons  ¹Ú»ó¹Î(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 17:40~17:45 Pros(rebuttal)  Á¶»óÈ£(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 17:45~17:50 Cons(rebuttal)  ¹Ú»ó¹Î(À»ÁöÀÇ´ë) 
Åä·Ð 11-06 Rooom B 17:50~18:15 ÆгΠÅäÀÇ  ±èÁöÈñ, Á¶Á¤¼±, ȲÈñÁ¤(°¡Å縯ÀÇ´ë, °¡Å縯ÀÇ´ë, °æÈñÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 17:00~17:20 °íÇ÷¾Ð ¾àÁ¦º¹¿ë ½Ã°£. ¾Æħ vs. Ãëħ Àü  À¯½Â±â(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 17:20~17:40 º¯µ¿ÀÌ ½ÉÇÑ °íÇ÷¾Ð ȯÀÚÀÇ Ä¡·á  Á¤ÁßÈ­(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 11-06 Rooom B 17:40~18:00 ¸¸¼º ÄáÆϺ´À» µ¿¹ÝÇÑ °íÇ÷¾Ð ȯÀÚÀÇ ½ÄÀÌ¿ä¹ý°ú ¾à¹°Ä¡·á  ¼ÕÀϼ®(°æÈñÀÇ´ë) 
Åä·Ð 11-06 Rooom B 18:00~18:15 ÆгΠÅäÀÇ  Á¶ÀºÁÖ, ±è±¤ÀÏ, ±è´ëÈñ(°¡Å縯ÀÇ´ë, ¼­¿ïÀÇ´ë, ¿ï»êÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦55ȸ Ãß°è±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2021-11-06""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ¿Ü°úÇÐȸ Annual Congress of KSS(Korean Surgical Society) 2021 (73Â÷ Çмú´ëȸ) 3ÀÏÂ÷ : 2021-11-06
´ÙÀ½±Û ´ë±¸°æºÏ°³¿ø³»°úÀÇ»çȸ Á¦25Â÷ Ãß°èÇмú´ëȸ(³­Ä¡¼º GERD, ¸¸¼ºº¯ºñ) : 2021-11-06
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 23 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 23 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 30 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 27 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 26 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 16 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 7 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 6 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 14 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 11 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 5 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 17 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 9 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 15 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 12 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷